Conformis, Inc. Appoints Medical Device Veteran to Chief Operating Officer
Burlington, Mass. – March 24, 2008 – Conformis, Inc., a privately held company that develops and commercializes minimally invasive medical devices for the treatment of osteoarthritis and joint damage, today announced the appointment of Philip (Phil) Licari to Chief Operating Officer. His addition to the Conformis leadership team comes at a time where the company is experiencing significant growth across North America and Europe for its expanding line of personalized, patient-specific implants and instrumentation.
Phil joins Conformis from NxStage Medical, a medical device company that develops, manufactures and markets products for the treatment of end-stage renal disease and acute kidney failure, where he served as Senior Vice President and Chief Operating Officer. Phil played a significant role in taking the company from an early stage dialysis products company, through its initial public offering and secondary financing. He developed a scalable operating infrastructure, including new manufacturing plants and a reliable supplier base as the business endured a sustained period of dramatic growth in unit shipments and annual revenues.
“This is an exciting period of growth for Conformis and we are pleased to welcome Phil to the team,” said Conformis Chairman and Chief Executive Officer Philipp Lang, MD. “With Phil’s proven track record of success in the medical device industry and ability to scale a business from early stage to IPO, there is no question he has the experience and leadership qualities that will allow us to reach our next stage of growth as a global organization.”
Prior to joining NXStage Medical, Phil held various senior operating positions with Boston Scientific for more than eight years, ranging from Vice President of Supply Chain and Logistics, to Vice President roles in Strategic Sourcing, Clinical Operations and National Accounts. He supported all divisions of the company and was instrumental in introducing and supporting many of Boston Scientific’s most successful product platforms. Phil’s leadership helped Boston Scientific through years of growth in profitability and operating capacity. Phil holds a B.S. in Biomedical Engineering from Tufts University and an M.B.A. from the University Of Chicago Graduate School Of Business.
“I’m joining Conformis at a very exciting time in the company’s history. The growth potential and business outlook for the company in the next 3-5 years is nothing short of extraordinary,” said Mr. Licari. “I look forward to working with the entire leadership team as we set our sights in becoming one of the dominant emerging players in the orthopedic market.”
About Conformis, Inc.
Conformis, Inc. is a privately held company incorporated in 2004 that develops and commercializes medical devices for the treatment of osteoarthritis and joint damages. The Company’s novel and scaleable ‘image-to-implant’ process is comprised of two related technology platforms. iFit™ Technology enables the creation of conforming, patient-specific implants that are precisely sized and shaped to match the 3D topography of the patient’s anatomic bone surfaces. The iJig™ Instrumentation enables the creation of novel disposable instrumentation that radically simplifies and improves the surgical process.
Both platforms are supported by proprietary, intellectual property consisting of more than 120 issued, allowed and pending patents or patent applications that span imaging software, image processing, implant design, surgical techniques and instrumentation.
To date, Conformis has developed a comprehensive line of minimally traumatic, bone and cartilage-preserving knee implants and instrumentation designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery. Each of these devices has been cleared by the US Food and Drug Administration for marketing in the U.S.
New Implant Technology, A New Twist On Knee Replacement
The Cape Cod Chronicle: ConforMIS, is breaking new ground in the field of knee replacements by offering something never seen before: customized knee implants designed and manufactured for each individual patient, with no two quite alike.
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
Data Shows a Low Cumulative Percent Revision of 0.5% for Conformis Patients vs 1.9% for all Total Knee Replacement Patients